Keyword Analysis & Research: beigene
Keyword Research: People who searched beigene also searched
Search Results related to beigene on Search Engine
-
BeiGene | Cancer Has No Borders. Neither Do We.
https://www.beigene.com/
Web1 day ago · BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide.
DA: 80 PA: 45 MOZ Rank: 77
-
BeiGene - Wikipedia
https://en.wikipedia.org/wiki/BeiGene
WebBeiGene, Ltd. is a global oncology company that specializes in the development of drugs for cancer treatment. Founded in 2010 chief executive officer by John V. Oyler and Xiaodong Wang , the multinational company headquartered in Cambridge, Massachusetts has offices in North America, Europe, South America, Asia and Australia.
DA: 17 PA: 21 MOZ Rank: 54
-
Our Mission, Vision & Values | BeiGene
https://www.beigene.com/about/our-company/mission-vision-values/
WebMission. Build the first next-generation oncology company – one that expands the highest quality therapies to more people around the world – through courage, persistent innovation, and challenging the status quo.
DA: 12 PA: 19 MOZ Rank: 43
-
Join Our Team | BeiGene
https://www.beigene.com/careers/
WebWe’re looking for highly motivated and collaborative colleagues interested in making a lasting impact in helping get impactful medicines to more people around the world. Find a Career.
DA: 21 PA: 15 MOZ Rank: 81
-
BeiGene Receives FDA Approval for TEVIMBRA® for the …
https://finance.yahoo.com/news/beigene-receives-fda-approval-tevimbra-202800347.html
WebMar 14, 2024 · BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., March 14, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug...
DA: 100 PA: 75 MOZ Rank: 39
-
BeiGene Announces FDA Accelerated Approval of BRUKINSA …
https://finance.yahoo.com/news/beigene-announces-fda-accelerated-approval-221900120.html
WebMar 7, 2024 · BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., March 07, 2024--BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug...
DA: 70 PA: 37 MOZ Rank: 80
-
Press Releases – NASDAQ (US) Website - BeiGene
https://ir.beigene.com/news-events/press-releases/
WebFeb 26, 2024. BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates read more... Feb 26, 2024. BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer read more... Jan 23, 2024.
DA: 88 PA: 41 MOZ Rank: 53
-
BeiGene | LinkedIn
https://www.linkedin.com/company/beigene
WebAbout us. BeiGene is a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. With a broad...
DA: 15 PA: 30 MOZ Rank: 76
-
BeiGene Announces Positive Regulatory Updates in Europe and …
https://www.businesswire.com/news/home/20230919543475/en/BeiGene-Announces-Positive-Regulatory-Updates-in-Europe-and-the-U.S.-After-Recently-Regaining-Global-Rights-for-TEVIMBRA%C2%AE/
WebSep 19, 2023 · BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®. European Commission approves TEVIMBRA for previously treated advanced or...
DA: 63 PA: 49 MOZ Rank: 75
-
NASDAQ (US) Website – NASDAQ Investor Overview - BeiGene
https://ir.beigene.com/
WebBeiGene Receives FDA Approval for TEVIMBRA® for the Treatment ... NASDAQ. HKEX. SSE. 20/04/2024 04:00. Last. 129.52. Change. -2.44 / -1.85% Previous Close. 131.96. Open. 130.00. High. 130.85. Low. Volume. Data delayed at least 15 minutes. Supplied by © Euroland.com. Terms of Service. IR Menu. Investor Presentation. March 8, 2024.
DA: 29 PA: 78 MOZ Rank: 77
